Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay

Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism reactions. Recently, the US FDA and EU EMA have suggested that CYP enzyme induction can be measured by both enzymatic activity and mRNA expression. H...

Full description

Saved in:
Bibliographic Details
Published inBiomolecules & therapeutics Vol. 23; no. 5; pp. 486 - 492
Main Authors Kim, Young-Hoon, Bae, Young-Ji, Kim, Hyung Soo, Cha, Hey-Jin, Yun, Jae-Suk, Shin, Ji-Soon, Seong, Won-Keun, Lee, Yong-Moon, Han, Kyoung-Moon
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Society of Applied Pharmacology 01.09.2015
한국응용약물학회
Subjects
Online AccessGet full text
ISSN2005-4483
1976-9148
1976-9148
2005-4483
DOI10.4062/biomolther.2015.041

Cover

Abstract Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism reactions. Recently, the US FDA and EU EMA have suggested that CYP enzyme induction can be measured by both enzymatic activity and mRNA expression. However, these experiments are time-consuming and their inter-assay variability can lead to misinterpretations of the results. To resolve these problems and establish a more powerful method to measure CYP induction, we determined CYP induction by using luminescent assay. Luminescent CYP assays link CYP enzyme activity to firefly luciferase luminescence technology. In this study, we measured the induction of CYP isozymes (1A2, 2B6, 2C9, and 3A4) in cryopreserved human hepatocytes (HMC424, 478, and 493) using a luminometer. We then examined the potential induction abilities (unknown so far) of mesalazine, a drug for colitis, and mosapride citrate, which is used as an antispasmodic drug. The results showed that mesalazine promotes CYP2B6 and 3A4 activities, while mosapride citrate promotes CYP1A2, 2B6, and 3A4 activities. Luminescent CYP assays offer rapid and safe advantages over LC-MS/MS and qRT-PCR methods. Furthermore, luminescent CYP assays decrease the interference between the optical properties of the test compound and the CYP substrates. Therefore, luminescent CYP assays are less labor intensive, rapid, and can be used as robust tools for high-throughput CYP screening during early drug discovery.
AbstractList Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism reactions. Recently, the US FDA and EU EMA have suggested that CYP enzyme induction can be measured by both enzymatic activity and mRNA expression. However, these experiments are time-consuming and their interassay variability can lead to misinterpretations of the results. To resolve these problems and establish a more powerful method to measure CYP induction, we determined CYP induction by using luminescent assay. Luminescent CYP assays link CYP enzyme activity to firefly luciferase luminescence technology. In this study, we measured the induction of CYP isozymes (1A2, 2B6, 2C9, and 3A4) in cryopreserved human hepatocytes (HMC424, 478, and 493) using a luminometer. We then examined the potential induction abilities (unknown so far) of mesalazine, a drug for colitis, and mosapride citrate, which is used as an antispasmodic drug. The results showed that mesalazine promotes CYP2B6 and 3A4 activities, while mosapride citrate promotes CYP1A2, 2B6, and 3A4 activities. Luminescent CYP assays offer rapid and safe advantages over LC-MS/MS and qRT-PCR methods. Furthermore, luminescent CYP assays decrease the interference between the optical properties of the test compound and the CYP substrates. Therefore, luminescent CYP assays are less labor intensive, rapid, and can be used as robust tools for high-throughput CYP screening during early drug discovery. KCI Citation Count: 9
Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism reactions. Recently, the US FDA and EU EMA have suggested that CYP enzyme induction can be measured by both enzymatic activity and mRNA expression. However, these experiments are time-consuming and their inter-assay variability can lead to misinterpretations of the results. To resolve these problems and establish a more powerful method to measure CYP induction, we determined CYP induction by using luminescent assay. Luminescent CYP assays link CYP enzyme activity to firefly luciferase luminescence technology. In this study, we measured the induction of CYP isozymes (1A2, 2B6, 2C9, and 3A4) in cryopreserved human hepatocytes (HMC424, 478, and 493) using a luminometer. We then examined the potential induction abilities (unknown so far) of mesalazine, a drug for colitis, and mosapride citrate, which is used as an antispasmodic drug. The results showed that mesalazine promotes CYP2B6 and 3A4 activities, while mosapride citrate promotes CYP1A2, 2B6, and 3A4 activities. Luminescent CYP assays offer rapid and safe advantages over LC-MS/MS and qRT-PCR methods. Furthermore, luminescent CYP assays decrease the interference between the optical properties of the test compound and the CYP substrates. Therefore, luminescent CYP assays are less labor intensive, rapid, and can be used as robust tools for high-throughput CYP screening during early drug discovery.
Author Cha, Hey-Jin
Seong, Won-Keun
Kim, Hyung Soo
Yun, Jae-Suk
Han, Kyoung-Moon
Lee, Yong-Moon
Kim, Young-Hoon
Shin, Ji-Soon
Bae, Young-Ji
AuthorAffiliation 1 Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700
2 College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea
AuthorAffiliation_xml – name: 1 Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700
– name: 2 College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea
Author_xml – sequence: 1
  givenname: Young-Hoon
  surname: Kim
  fullname: Kim, Young-Hoon
  organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea
– sequence: 2
  givenname: Young-Ji
  surname: Bae
  fullname: Bae, Young-Ji
  organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea
– sequence: 3
  givenname: Hyung Soo
  surname: Kim
  fullname: Kim, Hyung Soo
  organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea
– sequence: 4
  givenname: Hey-Jin
  surname: Cha
  fullname: Cha, Hey-Jin
  organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea
– sequence: 5
  givenname: Jae-Suk
  surname: Yun
  fullname: Yun, Jae-Suk
  organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea
– sequence: 6
  givenname: Ji-Soon
  surname: Shin
  fullname: Shin, Ji-Soon
  organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea
– sequence: 7
  givenname: Won-Keun
  surname: Seong
  fullname: Seong, Won-Keun
  organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea
– sequence: 8
  givenname: Yong-Moon
  surname: Lee
  fullname: Lee, Yong-Moon
  organization: College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea
– sequence: 9
  givenname: Kyoung-Moon
  surname: Han
  fullname: Han, Kyoung-Moon
  organization: Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety, Cheongju 363-700, Republic of Korea, College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26336590$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002019384$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9UsFuEzEQtVARTQtfgIR85JJge23v-oIUotJGSgRC6dlydmcb01072N5K6ZkPr7eBFjhw8Yw0782b8bwzdOK8A4TeUjLjRLIPW-t736UdhBkjVMwIpy_QhKpSThXl1QmaMELElPOqOEVnMX4nRJZUyFfolMmikEKRCfq5BhOHAD24hH2Lr4beOLw4JF_vgu8Bf-WC4At3f8j50jVDnax3-JOJ0OCcrCGaztxbB9i4Bq99NPtgG8ALm4JJgDcBTBq7R3wdrbvBBq-GPuNjPUrOYzSH1-hla7oIb37Fc3T9-WKzuJquvlwuF_PVtOZCpSkFqDhpCS1MpUpDpIKSNxWrFJEtaxmRBS15RRtWkir_CBRbKgQDWlBGtrQpztH7Y18XWn1bW-2NfYw3Xt8GPf-2WWqqlBRVhn48QvfDtodmnDWYTufdehMOj8S_K87ucps7zYWQjJJnrX3wPwaISfc2r9x1xoEfoqYlUSXl-c3Qd39qPYn8vlIGFEdAHXyMAdonCCV69IJ-9oIevaCzFzJL_cOqbTLj-fLAtvsv9wEmJb38
CitedBy_id crossref_primary_10_3390_medicina59020340
crossref_primary_10_3390_ht7040029
crossref_primary_10_1155_2021_9384663
crossref_primary_10_1186_s12991_017_0140_8
crossref_primary_10_1038_s41598_024_51781_6
crossref_primary_10_1016_j_dmpk_2019_08_006
crossref_primary_10_1080_00498254_2019_1588410
crossref_primary_10_1186_s13287_018_0910_5
crossref_primary_10_3390_pharmaceutics16111431
crossref_primary_10_1007_s12272_016_0748_2
crossref_primary_10_1016_j_bcp_2019_07_013
crossref_primary_10_3748_wjg_v25_i23_2846
crossref_primary_10_1016_j_ijpharm_2022_122282
Cites_doi 10.1517/17425255.2.4.629
10.1080/08998280.2000.11927719
10.1007/s11626-008-9085-1
10.1016/j.ccc.2006.02.004
10.1016/j.pharmthera.2012.12.007
10.1007/978-1-62703-321-3_1
10.3109/10408449209145319
10.1016/j.taap.2004.01.010
10.1517/17425255.4.1.103
10.1097/00054725-200409000-00019
ContentType Journal Article
Copyright Copyright © 2015, The Korean Society of Applied Pharmacology 2015
Copyright_xml – notice: Copyright © 2015, The Korean Society of Applied Pharmacology 2015
DBID AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.4062/biomolther.2015.041
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1976-9148
2005-4483
EndPage 492
ExternalDocumentID oai_kci_go_kr_ARTI_199658
PMC4556210
26336590
10_4062_biomolther_2015_041
Genre Journal Article
GroupedDBID ---
23N
5-W
5GY
8JR
9ZL
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
DU5
EF.
F5P
HYE
HZB
JDI
KQ8
M48
OK1
PGMZT
RPM
NPM
7X8
5PM
.UV
ACYCR
ID FETCH-LOGICAL-c459t-1ee840f013a897a069e74d828906f2f206317481d2708015e3b1552e13120b1d3
IEDL.DBID M48
ISSN 2005-4483
1976-9148
IngestDate Tue Nov 21 21:47:39 EST 2023
Thu Aug 21 18:19:46 EDT 2025
Fri Jul 11 03:29:37 EDT 2025
Thu Apr 03 07:04:05 EDT 2025
Thu Apr 24 23:12:37 EDT 2025
Tue Jul 01 04:15:27 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 5
Keywords CYP
Mesalazine
Human hepatocytes
Luminescent assay
Mosapride citrate
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c459t-1ee840f013a897a069e74d828906f2f206317481d2708015e3b1552e13120b1d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Kyoung-Moon Han and Young-Hoon Kim have contributed equally to this work.
G704-000363.2015.23.5.012
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.4062/biomolther.2015.041
PMID 26336590
PQID 1709714709
PQPubID 23479
PageCount 7
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_199658
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4556210
proquest_miscellaneous_1709714709
pubmed_primary_26336590
crossref_primary_10_4062_biomolther_2015_041
crossref_citationtrail_10_4062_biomolther_2015_041
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-09-01
PublicationDateYYYYMMDD 2015-09-01
PublicationDate_xml – month: 09
  year: 2015
  text: 2015-09-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Biomolecules & therapeutics
PublicationTitleAlternate Biomol Ther (Seoul)
PublicationYear 2015
Publisher The Korean Society of Applied Pharmacology
한국응용약물학회
Publisher_xml – name: The Korean Society of Applied Pharmacology
– name: 한국응용약물학회
References (OOOMB4_2015_v23n5_486_010) 2004; 199
(OOOMB4_2015_v23n5_486_013) 2013; 138
(OOOMB4_2015_v23n5_486_012) 1992; 22
(OOOMB4_2015_v23n5_486_006) 2012; 50
(OOOMB4_2015_v23n5_486_002) 2005; 3
(OOOMB4_2015_v23n5_486_001) 2013; 987
(OOOMB4_2015_v23n5_486_007) 2006; 22
(OOOMB4_2015_v23n5_486_011) 2004; 10
(OOOMB4_2015_v23n5_486_003) 2006; 2
(OOOMB4_2015_v23n5_486_005) 2008; 44
(OOOMB4_2015_v23n5_486_004) 2008; 4
(OOOMB4_2015_v23n5_486_009) 2000; 13
(OOOMB4_2015_v23n5_486_008) 2005; 13
23333322 - Pharmacol Ther. 2013 Apr;138(1):103-41
15472525 - Inflamm Bowel Dis. 2004 Sep;10(5):626-31
16082059 - Top HIV Med. 2005 Jun-Jul;13(2):79-83
23475663 - Methods Mol Biol. 2013;987:1-9
15364537 - Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209
1616599 - Crit Rev Toxicol. 1992;22(1):1-21
16389357 - Proc (Bayl Univ Med Cent). 2000 Oct;13(4):421-3
22541755 - Int J Clin Pharmacol Ther. 2012 Jul;50(7):524-31
16678003 - Crit Care Clin. 2006 Apr;22(2):329-45, vii
18427905 - In Vitro Cell Dev Biol Anim. 2008 May-Jun;44(5-6):129-34
18370862 - Expert Opin Drug Metab Toxicol. 2008 Jan;4(1):103-20
16859410 - Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):629-45
References_xml – volume: 2
  start-page: 629
  year: 2006
  ident: OOOMB4_2015_v23n5_486_003
  publication-title: Expert Opin. Drug Metab. Toxicol.
  doi: 10.1517/17425255.2.4.629
– volume: 13
  start-page: 421
  year: 2000
  ident: OOOMB4_2015_v23n5_486_009
  publication-title: Proc. (Bayl. Univ. Med. Cent.)
  doi: 10.1080/08998280.2000.11927719
– volume: 44
  start-page: 129
  year: 2008
  ident: OOOMB4_2015_v23n5_486_005
  publication-title: In Vitro Cell. Dev. Biol. Anim
  doi: 10.1007/s11626-008-9085-1
– volume: 22
  start-page: 329
  year: 2006
  ident: OOOMB4_2015_v23n5_486_007
  publication-title: Crit. Care Clin.
  doi: 10.1016/j.ccc.2006.02.004
– volume: 13
  start-page: 79
  year: 2005
  ident: OOOMB4_2015_v23n5_486_008
  publication-title: Top. HIV Med
– volume: 138
  start-page: 103
  year: 2013
  ident: OOOMB4_2015_v23n5_486_013
  publication-title: Pharmacol. Ther
  doi: 10.1016/j.pharmthera.2012.12.007
– volume: 987
  start-page: 1
  year: 2013
  ident: OOOMB4_2015_v23n5_486_001
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-62703-321-3_1
– volume: 22
  start-page: 1
  year: 1992
  ident: OOOMB4_2015_v23n5_486_012
  publication-title: Crit. Rev. Toxicol
  doi: 10.3109/10408449209145319
– volume: 50
  start-page: 524
  year: 2012
  ident: OOOMB4_2015_v23n5_486_006
  publication-title: Int. J. Clin. Pharmacol. Ther.
– volume: 3
  start-page: 9
  year: 2005
  ident: OOOMB4_2015_v23n5_486_002
  publication-title: Pharmacologyonline
– volume: 199
  start-page: 193
  year: 2004
  ident: OOOMB4_2015_v23n5_486_010
  publication-title: Toxicol. Appl. Pharmacol
  doi: 10.1016/j.taap.2004.01.010
– volume: 4
  start-page: 103
  year: 2008
  ident: OOOMB4_2015_v23n5_486_004
  publication-title: Expert Opin. Drug Metab. Toxicol.
  doi: 10.1517/17425255.4.1.103
– volume: 10
  start-page: 626
  year: 2004
  ident: OOOMB4_2015_v23n5_486_011
  publication-title: Inflamm. Bowel Dis.
  doi: 10.1097/00054725-200409000-00019
– reference: 18427905 - In Vitro Cell Dev Biol Anim. 2008 May-Jun;44(5-6):129-34
– reference: 16082059 - Top HIV Med. 2005 Jun-Jul;13(2):79-83
– reference: 22541755 - Int J Clin Pharmacol Ther. 2012 Jul;50(7):524-31
– reference: 23333322 - Pharmacol Ther. 2013 Apr;138(1):103-41
– reference: 16859410 - Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):629-45
– reference: 15364537 - Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209
– reference: 16389357 - Proc (Bayl Univ Med Cent). 2000 Oct;13(4):421-3
– reference: 18370862 - Expert Opin Drug Metab Toxicol. 2008 Jan;4(1):103-20
– reference: 15472525 - Inflamm Bowel Dis. 2004 Sep;10(5):626-31
– reference: 16678003 - Crit Care Clin. 2006 Apr;22(2):329-45, vii
– reference: 23475663 - Methods Mol Biol. 2013;987:1-9
– reference: 1616599 - Crit Rev Toxicol. 1992;22(1):1-21
SSID ssj0067156
Score 2.0656269
Snippet Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 486
SubjectTerms Original
약학
Title Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay
URI https://www.ncbi.nlm.nih.gov/pubmed/26336590
https://www.proquest.com/docview/1709714709
https://pubmed.ncbi.nlm.nih.gov/PMC4556210
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002019384
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Biomolecules & Therapeutics, 2015, 23(5), , pp.486-492
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKuXBBRby2hcpIPZLF7zQnBKtWBTWIQ1fqzXISm666TdpkV2I594d3xtndsqggcUksxY4Tj635xp75hpADhThABpk44ViiCs9hzWU8MaLkZWmK4CQGOOffzMlYfT3X51tklRV1OYDdg6Yd5pMat9Phz5vFR1jwgF-HoI7EBwxUb6aIl9BVSw8ZBrI_BtVk0BrL1fpYwaQ8pnON9Jtgl8iehuhvL9lQVY_qNjyEQv90pvxNOx3vkKdLWEk_9fPgGdny9XNym99vANIm0LhhT0eLWVNeIEsB_a40o0f1rwWUMYdHjHGgn0GxVRQKue_cNNJPU1dXNG86d91OKk9Hk8hpS89WXuodja4H1NHT-RU60uNnUhC9W7wg4-Ojs9FJssy6kJRKZ7OEew9GXwBo6A6z1DGT-VRVaJgxE0QQgGnAigGYK1JAm1x7WSCNm-eSC1bwSr4k23VT-9eEplVgJUAMLzHxn9OFZ14HBc2VZFUQAyJWA2zLJSU5ZsaYWjBNUCr2XioWpWJBKgPyft3oumfk-Hf1dyA5e1lOLDJp4_1HYy9bC_bCF4s-2PoQ6qzkamF14ZGJq30z7yxPkWNLwXVAXvVyXncqjJRGZ2xA0o0ZsK6A_W0-qScXkcFbaYCdnO3-36_skSdY7D3c3pDtWTv3bwESzYr9OM33417VHUE6DZw
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Measurement+of+Human+Cytochrome+P450+Enzyme+Induction+Based+on+Mesalazine+and+Mosapride+Citrate+Treatments+Using+a+Luminescent+Assay&rft.jtitle=Biomolecules+%26+therapeutics&rft.au=Kim%2C+Young-Hoon&rft.au=Bae%2C+Young-Ji&rft.au=Kim%2C+Hyung+Soo&rft.au=Cha%2C+Hey-Jin&rft.date=2015-09-01&rft.issn=2005-4483&rft.eissn=1976-9148&rft.volume=23&rft.issue=5&rft.spage=486&rft.epage=492&rft_id=info:doi/10.4062%2Fbiomolther.2015.041&rft.externalDBID=n%2Fa&rft.externalDocID=10_4062_biomolther_2015_041
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-4483&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-4483&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-4483&client=summon